• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    GE HealthCare Enters an Agreement to Distribute Flyrcado Through CDL Nuclear Technologies Group, a Leading Provider of Cardiac PET Imaging Equipment and Services in the U.S.

    9/8/25 9:14:00 AM ET
    $GEHC
    Medical Electronics
    Health Care
    Get the next $GEHC alert in real time by email
    • GE HealthCare's agreement with CardioNavix, a part of the CDL Nuclear Technologies services group, further broadens the reach of Flyrcado.
    • Through their nearly 225 U.S. customers, CDL and CardioNavix support more than 220,000 cardiac PET procedures annually.
    • This agreement builds the capabilities needed to support Flyrcado's growth in outpatient cardiac PET imaging by pairing CardioNavix's comprehensive program setup, workflow, and clinical and operations support with GE HealthCare's contract manufacturing organization (CMO) network to accelerate site enablement.

    GE HealthCare (NASDAQ:GEHC) today announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the CDL Nuclear Technologies services group that provides end-to-end cardiac positron emission tomography (PET) imaging solutions to hospitals and outpatient practices throughout the U.S. Through this agreement, GE HealthCare aims to bring Flyrcado™ (flurpiridaz F18) injection, its novel cardiac PET imaging agent, to patients nationwide, including private cardiology practices and office and hospital imaging settings, expanding the reach of cardiac PET for the evaluation of known or suspected coronary artery disease.

    Around six million myocardial perfusion imaging (MPI) procedures are performed each year in the U.S.1 Within that total, PET MPI represents roughly five to ten percent today2, and is increasingly utilized by U.S. cardiology practices.3 By strengthening delivery in office-based care, this collaboration is expected to accelerate adoption of Flyrcado, which in the multi-center international Phase III AURORA trial demonstrated higher diagnostic efficacy versus SPECT MPI for detecting coronary artery disease.4

    "This collaboration with CardioNavix is an important step in making Flyrcado available for patients nationwide, across all sites of care," said Eric Ruedinger, vice president and general manager of GE HealthCare's Pharmaceutical Diagnostics division for the U.S. and Canada. "CDL Nuclear Technologies is a trusted name in private cardiology and nuclear imaging, and today's announcement underscores the confidence both organizations have in Flyrcado's potential. This agreement helps establish the foundation needed to support GE HealthCare's vision for Flyrcado's growth in outpatient cardiac PET imaging and reinforces our commitment to innovation and patient-centered care."

    "We're proud that CardioNavix will be the first distributor to bring Flyrcado to private practice cardiology," said Lon Wilson, CEO of CDL Nuclear Technologies. "Through our nearly 225 customer sites, CDL and CardioNavix support around 220,000 patient procedures each year with end-to-end cardiac PET solutions—and that number continues to grow. Together with GE HealthCare, we're helping more providers bring advanced cardiac PET to patients in both private office-based settings and hospitals."

    The DSA supports GE HealthCare's long-term strategy to build the capabilities necessary for Flyrcado's success in outpatient settings. Initial roll-out will begin in late 2025 and accelerate into broader expansion throughout 2026.

    GE HealthCare's Pharmaceutical Diagnostics division is a global leader in imaging agents used to support around 130 million procedures per year globally, equivalent to four patient procedures every second. Its Molecular Imaging portfolio combines established proprietary products across cardiology, neurology and oncology, with an innovative pipeline, all aimed at enabling better informed diagnosis and monitoring for improved therapy decision making and clinical outcomes.

    About GE HealthCare Technologies Inc.

    GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

    GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.

    Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

    Forward-Looking Statements

    This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "plan," "believe," "anticipate," "intend," "potential," and similar expressions. These forward-looking statements may include, but are not limited to, statements about Flyrcado and GE HealthCare Technologies Inc.'s (the "Company's") performance, growth opportunities, and strategy; the rate of adoption and potential of Flyrcado; and the implementation and impact of the agreement. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company's actual results to differ materially from those described in its forward-looking statements include, but are not limited to, uncertainties regarding the commercial success of Flyrcado; the implementation and impact of the agreement; and decisions by regulatory authorities impacting labeling, manufacturing processes, safety, or other matters that could affect the availability or commercial potential of Flyrcado. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company's actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

    Important Safety Information and Usage of Flyrcado™ (flurpiridaz F 18) injection

    FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use important safety information

    Indications and Usage

    FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

    Contraindications

    None

    Warnings and Precautions

    • Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's prescribing information.
    • Radiation risks: FLYRCADO contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.

    Adverse Reactions

    • Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

    Use in Specific Populations

    • Pregnancy
    • There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure.
    • FLYRCADO contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy.
    • Lactation
    • Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration.
    • Pediatric Use
    • Safety and effectiveness of FLYRCADO in pediatric patients have not been established.

    To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch

    For full prescribing information, click here. For important safety information, please click here.

    JB12424US

     _________________

     

    1Miller, R. J. H., Bednarski, B. P., Pieszko, K., Kwiecinski, J., Williams, M. C., Shanbhag, A., Liang, J. X., Huang, C., Sharir, T., Hauser, M. T., Dorbala, S., Di Carli, M. F., Fish, M. B., Ruddy, T. D., Bateman, T. M., Einstein, A. J., Kaufmann, P. A., Miller, E. J., Sinusas, A. J., Acampa, W., Han, D., Dey, D., Berman, D. S., & Slomka, P. J. (2024). Clinical phenotypes among patients with normal cardiac perfusion using unsupervised learning: A retrospective observational study. EBioMedicine, 99, 104930. https://doi.org/10.1016/j.ebiom.2023.104930

    2GE HealthCare. (2024). Investor Day 2024 presentation: Pharmaceutical Diagnostics segment overview. Retrieved from https://investor.gehealthcare.com

    3Cardiovascular Business. (2024, September 12). Cardiac PET on the rise among U.S. cardiologists. Retrieved from https://cardiovascularbusiness.com

    4Maddahi, J., Orlandi, C., Packard, R. R. S., et al. (2023). Diagnostic performance of flurpiridaz F 18 PET myocardial perfusion imaging versus SPECT in the Phase III AURORA trial. Journal of the American College of Cardiology, 81(21), 2031–2044. https://doi.org/10.1016/j.jacc.2023.03.012

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250907726940/en/

    GE HealthCare Media Contact:

    Emmy Elguizaoui

    M +1 (978) 243-7503

    [email protected]

    Get the next $GEHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GEHC

    DatePrice TargetRatingAnalyst
    5/5/2025$73.00Sell → Neutral
    UBS
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    9/9/2024$90.00Neutral
    JP Morgan
    8/6/2024$100.00Buy
    Stifel
    5/30/2024$87.00Neutral
    Goldman
    More analyst ratings

    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare Enters an Agreement to Distribute Flyrcado Through CDL Nuclear Technologies Group, a Leading Provider of Cardiac PET Imaging Equipment and Services in the U.S.

    GE HealthCare's agreement with CardioNavix, a part of the CDL Nuclear Technologies services group, further broadens the reach of Flyrcado. Through their nearly 225 U.S. customers, CDL and CardioNavix support more than 220,000 cardiac PET procedures annually. This agreement builds the capabilities needed to support Flyrcado's growth in outpatient cardiac PET imaging by pairing CardioNavix's comprehensive program setup, workflow, and clinical and operations support with GE HealthCare's contract manufacturing organization (CMO) network to accelerate site enablement. GE HealthCare (NASDAQ:GEHC) today announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the

    9/8/25 9:14:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare unveils Vivid Pioneer, its most advanced AI-powered cardiovascular ultrasound system, designed to enhance speed and image quality for improved diagnostic confidence and workflow efficiency

    GE HealthCare (NASDAQ:GEHC) today announced the launch of the Vivid™ Pioneer, its most advanced, ultra-premium and adaptive cardiovascular ultrasound system yet, completely redesigned to support clinicians with extraordinary imaging in 2D, 4D and color flow, streamlined workflow, and enhanced diagnostic confidence. The ultrasound system recently received CE Mark and U.S. FDA 510(k) clearance. Cardiovascular diseases (CVDs) remain the leading cause of death in the world, accounting for nearly a third of all global deaths.i Reducing the burden of these diseases can be challenging, as their progression often goes unnoticed due to the asymptomatic nature of many CVDs in the early stages.ii Ea

    8/29/25 7:45:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare showcases integrated cardiology care pathway solutions and new AI-driven innovations at ESC 2025

    Solutions including ViewPoint EchoPilot™, CardIQ Suite™ and Revolution™ Vibe have been newly granted CE mark and aim to streamline cardiac workflows and improve diagnostic confidence across the care continuum Today, leading up to the European Society of Cardiology (ESC) Congress 2025, GE HealthCare (NASDAQ:GEHC) introduced its latest suite of cardiology innovations designed to enhance clinical decision-making, improve workflow efficiency, and support earlier diagnosis and treatment of cardiovascular disease (CVD)—the world's leading cause of death, responsible for an estimated 20.5 million deaths globally.i "Cardiovascular disease continues to place an immense and growing burden on he

    8/28/25 8:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GE HealthCare upgraded by UBS with a new price target

    UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

    5/5/25 8:34:55 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare upgraded by Goldman with a new price target

    Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

    3/11/25 7:35:30 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare upgraded by Jefferies with a new price target

    Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

    1/8/25 7:50:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G - GE HealthCare Technologies Inc. (0001932393) (Subject)

    8/13/25 4:35:15 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form 10-Q filed by GE HealthCare Technologies Inc.

    10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)

    7/30/25 6:27:45 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

    7/30/25 6:25:33 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/2/24 6:00:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Enterprise Oper. Officer Stacherski Kenneth R. covered exercise/tax liability with 892 shares, decreasing direct ownership by 2% to 40,996 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:19:36 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Chief People Officer Holton Adam Y covered exercise/tax liability with 464 shares, decreasing direct ownership by 3% to 16,768 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:18:39 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Chief Technology Officer Kass-Hout Taha covered exercise/tax liability with 2,897 shares, decreasing direct ownership by 4% to 64,950 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:17:20 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Leadership Updates

    Live Leadership Updates

    View All

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

    GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

    4/9/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare's MIM Software collaborates with Elekta to help enhance radiation therapy treatments and improve patient outcomes

    Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy

    4/22/24 7:07:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Financials

    Live finance-specific insights

    View All

    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    GE HealthCare reports second quarter 2025 financial results

    Revenue growth was 3% year-over-year; Organic revenue growth* was 2% Net income margin was 9.7% versus 8.9% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 14.6% versus 15.3% Diluted earnings per share (EPS) were $1.06 versus $0.93 for the prior year; Adjusted EPS* was $1.06 versus $1.00 Cash flow from operating activities was $94 million versus $(119) million for the prior year; Free cash flow* was $7 million versus $(182) million Raises full-year 2025 guidance GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2025. GE HealthCare President and CEO Peter Arduini said, "We were pleas

    7/30/25 6:20:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare to announce second quarter 2025 results on July 30, 2025

    GE HealthCare (NASDAQ:GEHC) will announce its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno

    7/7/25 8:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare announces cash dividend for second quarter of 2025

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more

    7/1/25 8:34:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    10/22/24 4:16:16 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by GE HealthCare Technologies Inc. (Amendment)

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    4/2/24 4:07:29 PM ET
    $GEHC
    Medical Electronics
    Health Care